Connect with us

News

First Human Trials of Ebola Vaccine to Start Next Week

Published

on

(PNA/Xinhua) — The U.S. government announced Thursday it will start initial human testing of an investigational vaccine next week to prevent infection of the Ebola virus that has killed more than 1,500 people in West Africa.

The U.S. National Institutes of Health (NIH) said in a statement that the phase one clinical trial will determine if a vaccine, co-developed by the agency’s National Institute of Allergy and Infectious Diseases (NIAID) and GlaxoSmithKline (GSK), is safe and induces an adequate immune response.

Testing will take place at the NIH’s clinical center in Bethesda, Maryland, with 20 healthy adults aged 18 to 50 years receiving an intramuscular injection of the vaccine, it said.

In parallel, the NIH and a British-based international consortium, including the Wellcome Trust, will test the NIAID/GSK vaccine among healthy volunteers in the United Kingdom and in the West African countries of Gambia and Mali, the agency said.

The U.S. government is also discussing a trial of the vaccine in Nigeria, Africa’s most populous country.

The NIH also said it will launch phase one clinical trials of another experimental Ebola vaccine developed by Canada’s Public Health Agency in the fall.

“There is an urgent need for a protective Ebola vaccine, and it is important to establish that a vaccine is safe and spurs the immune system to react in a way necessary to protect against infection,” NIAID Director Anthony Fauci said in the NIH press release.

According to the NIH, the NIAID/GSK Ebola vaccine is based on a type of chimpanzee cold virus, called chimp adenovirus type 3. The cold virus is used as a carrier, or vector, to deliver segments of genetic material derived from two Ebola virus species: Sudan Ebola and Zaire Ebola, which is the one circulating in West Africa.

The vaccine delivers the Ebola genetic material to human cells but does not replicate further. Rather, it allows the vaccine recipient’s cells to express a protein, and that protein prompts an immune response in the individual, the NIH said.

As it does contain the Ebola genetic material, it is important to know if the investigational vaccine will cause a vaccinated individual to become infected with Ebola.

“The experimental NIAID/GSK vaccine performed extremely well in protecting nonhuman primates from Ebola infection,” Fauci noted.

In response to the ongoing Ebola virus outbreak in West Africa, the pace of human safety testing for experimental Ebola vaccines has been expedited recently.

According to the World Health Organization, at least 1,552 suspected and confirmed deaths from Ebola infection have been reported in Guinea, Liberia, Nigeria, and Sierra Leone since the outbreak of the deadly virus was first reported in March 2014.

Clinical development for a vaccine is a three-phase process. During phase one, researchers test an investigational vaccine in a small group of people to evaluate its safety and the immune response it provokes. Phase two clinical trials of investigational vaccines are designed to further assess safety and immune response in larger numbers of volunteers. Phase three clinical trials are directed predominantly at determining vaccine’s ability to prevent infection or disease known as efficacy. (PNA/Xinhua) FPV/JSD

Continue Reading
Advertisement
Comments

Subscribe

Advertisement

Facebook

Advertisement

Ads Blocker Image Powered by Code Help Pro

It looks like you are using an adblocker

Please consider allowing ads on our site. We rely on these ads to help us grow and continue sharing our content.

OK
Powered By
Best Wordpress Adblock Detecting Plugin | CHP Adblock